Bayer Aktienges Ads (BAYRY) 104.0700 $BAYRY
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 228.55 (-3.00), PFE: 34.47 (-0.28), PRTK: 13.24 (-0.04)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 44.86 (-0.27), MON: 107.16 (-0.52), EA: 74.80 (-0.71), PFE: 34.47 (-0.28), SYY: 49.97 (-0.10), STZ: 153.65 (-1.19), XOM: 91.17 (-0.36), PEP: 103.74 (-0.34), NVDA: 47.23 (-0.04), DD: 68.07 (+0.52), PG: 83.57 (+0.16), CVX: 102.29 (-0.95), DOW: 53.22 (-0.05), PPG: 107.81 (-0.25), ECL: 119.44 (+0.01)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 91.92 (-0.71), GS: 148.14 (-0.21), MON: 107.16 (-0.52), JPM: 62.71 (-0.24), C: 42.68 (-0.24), WFC: 46.97 (-0.26), BAC: 13.61 (-0.01), ULTA: 238.23 (-2.24), TOL: 27.17 (-0.25), BHI: 46.06 (-0.54)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 107.16 (-0.52)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 47.39 (+0.05), SYT: 79.53 (-0.45), MON: 107.16 (-0.52), MOO: 48.69 (-0.21), VEGI: 23.45 (-0.52), IYM: 77.93 (-0.02), DD: 68.07 (+0.52), DOW: 53.22 (-0.05)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 107.16 (-0.52)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 48.86 (+0.68), MON: 107.16 (-0.52), PFE: 34.47 (-0.28), BAC: 13.61 (-0.01), CBS.A: 57.14 (+0.14), BA: 131.77 (+0.25), VIAB: 44.03 (+0.50), CBS: 53.65 (+0.21)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 107.16 (-0.52)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 48.86 (+0.68), MON: 107.16 (-0.52), CBS: 53.65 (+0.21)
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 23, 8:30AM CDT
Bayer (BAYRY) to acquire all issued and outstanding shares of common stock of Monsanto (MON) at $122 per share in an aggregate all-cash offer worth $62 billion.
MON: 107.16 (-0.52), PFE: 34.47 (-0.28), BMY: 72.31 (+1.06)
Fitch: Bayer-Monsanto Combination Challenged
BusinessWire - Thu May 19, 11:36AM CDT
A potential combination of chemical companies Bayer AG and Monsanto Company makes strategic sense given their complementary strengths, according to Fitch Ratings. However, Monsanto has a viable go-it-alone strategy to drive growth and Bayer is a larger, more diversified company whose growth is not solely dependent on agricultural drivers.
Bayer takeover of Monsanto would create global giant
By DAVID RISING and DAVID McHUGH - AP - Thu May 19, 11:08AM CDT
BERLIN (AP) — Bayer's potential acquisition of Monsanto would create a giant seed and farm chemical company with a strong footprint in the U.S., Europe and Asia, combining two businesses with complementary geographical focus.
MON: 107.16 (-0.52), DD: 68.07 (+0.52), DOW: 53.22 (-0.05)
Monsanto Comments on Recent Media Reports
BusinessWire - Wed May 18, 9:30PM CDT
In response to recent media reports, Monsanto Company (NYSE: MON) disclosed that it has received an unsolicited, non-binding proposal from Bayer AG for a potential acquisition of Monsanto, subject to due diligence, regulatory approvals and other conditions. The Board of Directors of Monsanto is reviewing the proposal, in consultation with its financial and legal advisors. Monsanto will have no further comment until its Board of Directors has completed its review. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 107.16 (-0.52), MS: 26.39 (+0.19)
Bayer Stops Phase II Adempas Study Due to Safety Issues
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:33AM CDT
Bayer (BAYRY) has terminated a phase II study on Adempas in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias, with immediate effect.
ANIP: 52.79 (+1.43), ADAP: 8.88 (-0.10), BMY: 72.31 (+1.06)
Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu May 05, 9:42AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected first-quarter 2016 earnings of $1.45 per share.
ANIP: 52.79 (+1.43), SNY: 40.29 (+0.50), REGN: 351.92 (+6.78)
Paratek Reports Positive Phase III Data on Antibiotic Drug
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:03AM CDT
Paratek Pharmaceuticals (PRTK) announced positive phase III results on omadacycline for the treatment of acute bacterial skin and skin structure infections.
AGN: 228.55 (-3.00), PFE: 34.47 (-0.28), PRTK: 13.24 (-0.04)
Philip Blake of Bayer Recognized in STEMconnector's® 100 CEO Leaders in STEM
PR Newswire - Thu Jun 16, 11:49AM CDT
Philip Blake, President of Bayer Corporation and Head of the Americas Region for Pharmaceuticals, has been recognized in STEMconnector's® 100 CEO Leaders in STEM publication.
Stock Market News for June 01, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:10AM CDT
Benchmarks ended mostly in the red on Tuesday following a cautious stance among investors ahead of the release of major economic reports this week
KO: 44.86 (-0.27), MON: 107.16 (-0.52), EA: 74.80 (-0.71), PFE: 34.47 (-0.28), SYY: 49.97 (-0.10), STZ: 153.65 (-1.19), XOM: 91.17 (-0.36), PEP: 103.74 (-0.34), NVDA: 47.23 (-0.04), DD: 68.07 (+0.52), PG: 83.57 (+0.16), CVX: 102.29 (-0.95), DOW: 53.22 (-0.05), PPG: 107.81 (-0.25), ECL: 119.44 (+0.01)
Stock Market News for May 31, 2016
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Benchmarks finished in the green on Friday after Fed Chairwoman Janet Yellen said a rate rise might be appropriate in coming months
DLTR: 91.92 (-0.71), GS: 148.14 (-0.21), MON: 107.16 (-0.52), JPM: 62.71 (-0.24), C: 42.68 (-0.24), WFC: 46.97 (-0.26), BAC: 13.61 (-0.01), ULTA: 238.23 (-2.24), TOL: 27.17 (-0.25), BHI: 46.06 (-0.54)
Monsanto rejects $62B Bayer bid, but still open to talks
AP - Tue May 24, 5:10PM CDT
NEW YORK (AP) — Monsanto rejected Bayer's $62 billion takeover bid, calling it "incomplete and financially inadequate."
MON: 107.16 (-0.52)
ETFs to Watch on Monsanto Buyout Offer
Sweta Killa - Zacks Investment Research - Tue May 24, 8:46AM CDT
The German chemical giant made all-cash bid to acquire Monsanto for $62 billion, including debt, putting these ETFs on spotlight.
XLB: 47.39 (+0.05), SYT: 79.53 (-0.45), MON: 107.16 (-0.52), MOO: 48.69 (-0.21), VEGI: 23.45 (-0.52), IYM: 77.93 (-0.02), DD: 68.07 (+0.52), DOW: 53.22 (-0.05)
How would Bayer-Monsanto affect workers, farmers, investors?
By DAVID McHUGH - AP - Mon May 23, 4:32PM CDT
FRANKFURT, Germany (AP) — Bayer wants to buy Monsanto for $62 billion, hooking up the German chemical and drug company with the St. Louis-based producer of seeds and weed-killers.
MON: 107.16 (-0.52)
Business Highlights
By The Associated Press - AP - Mon May 23, 4:30PM CDT
___
VIA: 48.86 (+0.68), MON: 107.16 (-0.52), PFE: 34.47 (-0.28), BAC: 13.61 (-0.01), CBS.A: 57.14 (+0.14), BA: 131.77 (+0.25), VIAB: 44.03 (+0.50), CBS: 53.65 (+0.21)
Bayer and Monsanto could combine plant, pet, people products
By LINDA A. JOHNSON and MATTHEW PERRONE - AP - Mon May 23, 4:05PM CDT
A merger between Bayer and Monsanto would put together two giant chemical makers, one focused on plants and another that also makes products for people and animals. Here's a look at their products, which have more than $65 billion in total annual revenue.
MON: 107.16 (-0.52)
Viacom (VIA) Redstone Drama Rivals Original Programming
Mark Vickery - Zacks Investment Research - Mon May 23, 9:36AM CDT
A power play is ongoing at the board of National Amusements, majority shareholders at Viacom and CBS.
VIA: 48.86 (+0.68), MON: 107.16 (-0.52), CBS: 53.65 (+0.21)
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
Zacks Equity Research - Zacks Investment Research - Mon May 23, 8:30AM CDT
Bayer (BAYRY) to acquire all issued and outstanding shares of common stock of Monsanto (MON) at $122 per share in an aggregate all-cash offer worth $62 billion.
MON: 107.16 (-0.52), PFE: 34.47 (-0.28), BMY: 72.31 (+1.06)
Fitch: Bayer-Monsanto Combination Challenged
BusinessWire - Thu May 19, 11:36AM CDT
A potential combination of chemical companies Bayer AG and Monsanto Company makes strategic sense given their complementary strengths, according to Fitch Ratings. However, Monsanto has a viable go-it-alone strategy to drive growth and Bayer is a larger, more diversified company whose growth is not solely dependent on agricultural drivers.
Bayer takeover of Monsanto would create global giant
By DAVID RISING and DAVID McHUGH - AP - Thu May 19, 11:08AM CDT
BERLIN (AP) — Bayer's potential acquisition of Monsanto would create a giant seed and farm chemical company with a strong footprint in the U.S., Europe and Asia, combining two businesses with complementary geographical focus.
MON: 107.16 (-0.52), DD: 68.07 (+0.52), DOW: 53.22 (-0.05)
Monsanto Comments on Recent Media Reports
BusinessWire - Wed May 18, 9:30PM CDT
In response to recent media reports, Monsanto Company (NYSE: MON) disclosed that it has received an unsolicited, non-binding proposal from Bayer AG for a potential acquisition of Monsanto, subject to due diligence, regulatory approvals and other conditions. The Board of Directors of Monsanto is reviewing the proposal, in consultation with its financial and legal advisors. Monsanto will have no further comment until its Board of Directors has completed its review. There is no assurance that any transaction will be entered into or consummated, or on what terms.
MON: 107.16 (-0.52), MS: 26.39 (+0.19)
Bayer Stops Phase II Adempas Study Due to Safety Issues
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:33AM CDT
Bayer (BAYRY) has terminated a phase II study on Adempas in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias, with immediate effect.
ANIP: 52.79 (+1.43), ADAP: 8.88 (-0.10), BMY: 72.31 (+1.06)
Regeneron (REGN) Tops Q1 Earnings, Ups 2016 Eylea View
Zacks Equity Research - Zacks Investment Research - Thu May 05, 9:42AM CDT
Regeneron Pharmaceuticals (REGN) reported better-than-expected first-quarter 2016 earnings of $1.45 per share.
ANIP: 52.79 (+1.43), SNY: 40.29 (+0.50), REGN: 351.92 (+6.78)
